Objective To study of neoadjuvant chemotherapy for advanced gastric cancer postoperative pathological changes and clinical effect. Methods: 50 cases of advanced gastric cancer were randomly divided into two groups, the study group of 25 cases of arterial infusion chemotherapy with oxaliplatin; the control group of 25 cases of systemic venous chemotherapy. The former uses Seldinger technology, according to lesion location selectivearterial corresponding, oxaliplatin 85mg/m2 chemotherapy regimen tegafur, doxorubicin, 1000mg/m2 25mg/ m2. The two cycle 7-10 days after operation treatment; the latter 25 patients selected 85mg/m2 D1 oxaliplatin, calcium folinate 200 mg/m2 D1-2, fluorouracil 400 mg/m2ivd1-2, 600 mg/m2 CIVd1-2 fluorouracil. The two cycle of chemotherapy treatment 10-14 days after operation, the postoperative gastric cancer specimens for examination and surgery pathology after 2 year survival rate. Results: the two groups of postoperative pathology change and total effective rate were 55.6%, 36.52%. A significant difference between two groups (P < 0.05). The 2 year survival rates were 70% and 54.2%, a significant difference between two groups (P < 0.05). Conclusion: neoadjuvant preoperative interventional chemotherapy containing oxaliplatin is a safe, effective, feasible treatment method for advanced gastric cancer, complications less than systemic chemotherapy, the operation resection rate and survival rate increased, to study the large sample.
NETL
NSTL
万方数据
